Effect of cytosine arabinoside on Herpes virus infection in renal allograft recipients.
Cytosine arabinoside (Ara-C) was used for treatment of severe symptomatic cytomegalovirus (CMV)-herpes infections that were seen in nineteen of 174 renal allograft recipients. Ara-C was administered by continuous intravenous infusion at a mean dose of 35 mg/m2 daily for three to four days. Side effects were few and minor in nature. All cases of herpes simplex and herpes zoster, which usually have a prolonged and sometimes unfavorable course in immunosuppressed patients, cleared promptly with no recurrence. All nine patients, except one who had CMV infection with the symptom complex of fever and retinitis or pneumonitis, responded satisfactorily. In the three patients in whom the CMV titers were available, there was a significant decrease in titer within two weeks after treatment. This pilot study of Ara-C in treatment of CMV-herpes infections in immunosuppressed renal allograft recipients suggests a degree of efficacy and safety in the drug that would justify a carefully designed, controlled study.
D000328:Adult; D003561:Cytarabine / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000188:drug therapy*; D006561:Herpes Simplex / Q000188:drug therapy*; D006562:Herpes Zoster / Q000188:drug therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D007677:Kidney Function Tests; D016030:Kidney Transplantation; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy*; D014184:Transplantation, Homologous; D014945:Wound Healing / Q000187:drug effects
D003561:Cytarabine